These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 1328412

  • 1. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder.
    Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DL.
    J Infect Dis; 1992 Nov; 166(5):986-94. PubMed ID: 1328412
    [Abstract] [Full Text] [Related]

  • 2. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Nov; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 3. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 4. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 15; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 5. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, Weir MA, House AA.
    Transpl Infect Dis; 2016 Jun 15; 18(3):423-30. PubMed ID: 27016725
    [Abstract] [Full Text] [Related]

  • 6. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G.
    New Microbiol; 2003 Apr 15; 26(2):141-9. PubMed ID: 12737195
    [Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
    Doesch AO, Konstandin M, Celik S, Kristen A, Frankenstein L, Sack FU, Schnabel P, Schnitzler P, Katus HA, Dengler TJ.
    Transpl Int; 2008 Oct 15; 21(10):963-71. PubMed ID: 18564989
    [Abstract] [Full Text] [Related]

  • 8. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
    Choquet S, Varnous S, Deback C, Golmard JL, Leblond V.
    Am J Transplant; 2014 Apr 15; 14(4):857-66. PubMed ID: 24666832
    [Abstract] [Full Text] [Related]

  • 9. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B, Riella LV, Dierickx D.
    Am J Kidney Dis; 2021 Aug 15; 78(2):272-281. PubMed ID: 33774079
    [Abstract] [Full Text] [Related]

  • 10. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL.
    J Pediatr Gastroenterol Nutr; 2001 Oct 15; 33(4):445-9. PubMed ID: 11698761
    [Abstract] [Full Text] [Related]

  • 11. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders.
    Limaye AP, Huang ML, Atienza EE, Ferrenberg JM, Corey L.
    J Clin Microbiol; 1999 Apr 15; 37(4):1113-6. PubMed ID: 10074534
    [Abstract] [Full Text] [Related]

  • 12. [Evaluation of PCR results in the diagnosis of Epstein-Barr virus infections].
    Karadağ Geçgel S, Ersoy A, Sevinir BB, Sınırtaş M, Göral G.
    Mikrobiyol Bul; 2012 Oct 15; 46(4):594-606. PubMed ID: 23188573
    [Abstract] [Full Text] [Related]

  • 13. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb 15; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 14. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
    Birkeland SA, Andersen HK, Hamilton-Dutoit SJ.
    Transplantation; 1999 May 15; 67(9):1209-14. PubMed ID: 10342310
    [Abstract] [Full Text] [Related]

  • 15. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
    Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA.
    Transplantation; 1993 Jul 15; 56(1):88-96. PubMed ID: 8333073
    [Abstract] [Full Text] [Related]

  • 16. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar 15; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W.
    Transplantation; 2007 Feb 27; 83(4):433-8. PubMed ID: 17318076
    [Abstract] [Full Text] [Related]

  • 18. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA.
    Transplantation; 2007 Jun 15; 83(11):1423-8. PubMed ID: 17565314
    [Abstract] [Full Text] [Related]

  • 19. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL.
    Clin Transplant; 1995 Feb 15; 9(1):53-9. PubMed ID: 7742583
    [Abstract] [Full Text] [Related]

  • 20. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft.
    Yousem SA, Randhawa P, Locker J, Paradis IL, Dauber JA, Griffith BP, Nalesnik MA.
    Hum Pathol; 1989 Apr 15; 20(4):361-9. PubMed ID: 2539321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.